News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford Gene Technology Ltd. Awarded Best Medtech Dealmaker by Oxford Bioscience Network for 58-Gene Cancer Profiling Panel



10/8/2013 9:14:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oxford, UK – 8 October 2013 – Oxford Gene Technology (OGT), a provider of innovative genetics research and biomarker solutions to advance molecular medicine, has won the Best Medtech Dealmaker award at the 2013 Oxford Bioscience Network (OBN) awards held on Wednesday 2 October. The award recognises OGT’s collaboration with the Birmingham and Salisbury NHS Regional Genetics Laboratories to develop and launch a 58-gene solid tumour profiling service to advance vital research into personalised cancer care.

The panel, which includes important genes in breast, prostate, ovarian, lung and colorectal cancers, was developed in partnership with research teams at the centres in Birmingham and Salisbury as part of a £1.16 million funding award from the UK Government-backed Technology Strategy Board’s Stratified Medicines programme. The NHS teams played a key part in the development of the service, validating the tumour profiling assay across different sample types.

Dr Jon Rees, CEO, Oxford Bioscience Network said: “The nature of the collaboration between OGT and Birmingham and Salisbury NHS Regional Genetics Laboratories was of great interest to the OBN Advisory Board, especially as a reflection of the current momentum in healthcare partnerships. The launch of the service in May is testament to how a collaboration of this type can succeed.”

Tim Hall, CFO, who accepted the award for OGT, said, “We value our partnership with the Birmingham and Salisbury NHS Regional Genetics Laboratories very highly. We are pleased that the OBN advisory board recognised the benefits that collaborations between research and industry can bring in the development of ground-breaking medical technologies.”

OGT’s SureSeq™ Solid Tumour Panel Sequencing Service was launched in May 2013, enabling researchers to identify both known and new mutations to develop informed, personalised cancer treatment strategies. OGT is continuing its work with the research teams in Birmingham and Salisbury to develop the solid tumour profiling assay as a product for launch in early 2014.

For more information, please contact:

Oxford Gene Technology

Stephen Archibald, Director of Communications

T: +44 (0) 1865 856826

F: +44 (0) 1865 848684

E: contact@ogt.com

W: www.ogt.com

College Hill (PR Agency for OGT)

Melanie Toyne Sewell / Jen Lewis

T: +44 (0) 20 7457 2029

E: OGT@collegehill.com

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The Company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

For more information on the Company, please visit our website at www.ogt.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES